Navigation Links
Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 19, 2007 - Amgen (NASDAQ: AMGN) today announced the results of the "145 study", a randomized, double-blind, placebo-controlled, multicenter Phase 3 study of Aranesp(R) (darbepoetin alfa) in 600 previously untreated patients with extensive-stage small-cell lung cancer (SCLC) receiving platinum-containing chemotherapy. The study demonstrated no statistically significant difference in risk of death (overall survival Aranesp compared to placebo Hazard Ratio (HR): 0.93, 95% CI: 0.78 to 1.11) or investigator determined progression-free survival (HR: 1.02, 95% CI: 0.86 to 1.21).

The study demonstrated a significant change in hemoglobin concentration from baseline in favor of Aranesp (a co-primary endpoint). Aranesp-treated patients also experienced a significantly lower risk of blood transfusions (HR: 0.40, 95% CI: 0.29 to 0.55). The overall safety profile, including thromboembolic events, was consistent with that described in the U.S. label.

"The 145 study is a component of Amgen's ongoing pharmacovigilance program designed to evaluate the effect of Aranesp on long-term survival in patients with chemotherapy-induced anemia. This study had higher initiation and maintenance hemoglobin targets (Hb less than or equal to 13 g/dl) than in the U.S. label," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "These results contribute to the growing body of evidence on ESA safety, reinforcing the neutral impact of ESAs on survival in cancer patients suffering from chemotherapy-induced anemia."

Amgen initiated the SCLC study in 2002 after results from a previous Phase 3 study showed a trend towards improved survival in patients with lung cancer. The 145 study was designed to evaluate whether increasing or maintaining hemoglobin concentrations with Aranesp, when administered with platinum-containing chemotherapy in patien
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
6. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
7. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
10. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
11. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
Post Your Comments:
(Date:8/20/2014)... Aug. 20, 2014  Quantum Materials Corporation (OTCQB:QTMM) ... of patent families from Bayer Technology Services GmbH, the ... Bayer AG of Leverkusen, Germany ... broad intellectual property protection for advances Quantum ... dot (QD) manufacturing. In addition, the Bayer patents ...
(Date:8/20/2014)... 20, 2014 Phase I Trial ... US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology company ... announces that it has begun a Phase I, First ... KVD001, for the treatment of DME. The study,s Principal ... Eye Institute, Joslin Diabetes Center; Harvard Medical School Department ...
(Date:8/19/2014)... Ala. , Aug. 19, 2014  The Alabama Supreme ... that patients can sue drug makers who mislead doctors into ... harmful side‑effects.  The case is Weeks v. Wyeth, and the ... makers in that same case last year. Heninger Garrison Davis ... represent the patient in the case, Danny Weeks . ...
Breaking Medicine Technology:Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4
... N.J., July 30 Covance Inc. ... supplementary accreditation for the conduct of clinical pharmacology in Europe by ... accreditation process provides clinical trial volunteers and sponsors with confidence that ... , , This accreditation was awarded to ...
... , BEDFORD, Mass., July 30 VisEn Medical ... from research through medicine, announced today that scientists reporting in ... disease-related biologic pathway using an integrated and innovative array of ... imaging technologies. The newly reported biologic pathway relates ...
Cached Medicine Technology:Covance Receives Highest Level of Phase I Accreditation 2VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE 2VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE 3
(Date:8/20/2014)... 20, 2014 According to a ... "Multiplexed Diagnostics Market (Technologies: Very High, High, Medium, ... Disease Diagnosis, Oncology, Autoimmune Diseases, Cardiac, Allergies and ... Trends and Forecast, 2013 - 2019", the global ... billion in 2012 and is expected to grow ...
(Date:8/20/2014)... commemorate the 100th anniversary of a revolutionary technique that ... News (C&EN) magazine last week released a special ... a tantalizing glimpse of its future. C&EN is the ... the world,s largest scientific society. , The technique got ... the first paper on X-ray diffraction from a crystal ...
(Date:8/20/2014)... 2014 Transrectal ultrasound guided biopsy is the gold ... suggested that the number of risks associated with the ... Swedish researchers found that six percent of men filled ... within 30 days after having a prostate biopsy, with ... reports The Journal of Urology . , Earlier ...
(Date:8/20/2014)... August 20, 2014 According ... by Type (Acrylonitrile butadiene styrene, Fluor polymer, ... Applications and Geography - Trends & Forecasts ... engineering plastics market with analysis and forecasting ... also identifies the driving and restraining factors ...
(Date:8/20/2014)... August 20, 2014 Ticket Down is ... in Miami, FL at the Sun Life Stadium in early September. ... this September when Brazil and Colombia meet at Sun Life Stadium ... top 10 teams in the world and will be a rematch ... The match will kick-off on Sept. 5 and will feature some ...
Breaking Medicine News(10 mins):Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Severe infections with hospitalization after prostate biopsy rising in Sweden 2Health News:Engineering Plastics Market Worth $79,026.6 Million by 2018 – New Report by MarketsandMarkets 2Health News:Engineering Plastics Market Worth $79,026.6 Million by 2018 – New Report by MarketsandMarkets 3Health News:Engineering Plastics Market Worth $79,026.6 Million by 2018 – New Report by MarketsandMarkets 4Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Match 2Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Match 3
... Ceylan, from Turkey evaluated their experience in 48 cases ... ages ranged from 5 months to 24 years with ... performed at various centers or during religious ceremonies in ... found that the most commonly observed complication was preputio-glandular ...
... toxic chemicals and industrial effluents in sea and soil could increase ... obesity was thought to be the most important factor in the ... body does not produce enough insulin - necessary for the body ... by South Korean researchers has shown that people whose bodies are ...
... casts a shadow the length of a lifetime.” , - Herbert ... Sana was home alone, happy in her imaginative world of fairies ... neighborhood household. A knock on the door jolted her out of ... man, her uncle, was a devil in disguise. He locked the ...
... men, the erectile-dysfunction drugs Viagra, Cialis, and Levitra are ... in Midlife and Beyond,// a new report from Harvard ... the emotional and relationship pressures that frequently accompany erectile ... work only if the man is feeling sexual desire ...
... Australia’s already pressured hospital system would struggle to cope ... of a large-scale emergency, say trauma and emergency specialists.// ... preparedness targets for Australasian hospitals, says Dr Anthony Joseph, ... ,In the latest Medical Journal of ...
... A study conducted recently has shown that students who ... tendencies // like those who did not participate in ... not create the desired positive impact. ... being spent by the Federal government annually on the ...
Cached Medicine News:Health News:Child Abuse - When God’s Gifts Land in Devils’ Clutch 2Health News:Child Abuse - When God’s Gifts Land in Devils’ Clutch 3Health News:Can Our Hospitals Cope In A Disaster? 2
... When the all silicone cuff ... no distinguishable dimension to the ... shaft, yet it can be ... varied airway management needs. TTS™ ...
... Adjustable Neck Flange Hyperflex™ Tracheostomy TubesSimilar ... tube features the more traditional and ... Aire-Cuf® Adjustable Neck Flange Hyperflex™ Tracheostomy ... wedge, and obturator/introducer device., ,NOTE: ...
... for easy ventilator circuit attachment with or ... tubes are available in five adult sizes, ... system allows quick identification and correct sizing ... ,The Portex® line of D.I.C.® tracheostomy tubes ...
Indications For Usage: ,For use with percutaneous tracheotomies...
Medicine Products: